BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION Biosino Bio-Technology and Science Incorporation Stock
Equities
8247
CNE100000288
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.94 HKD | 0.00% |
|
+34.29% | +17.50% |
| Sales 2022 | 373M 51.54M 403M | Sales 2023 | 289M 39.94M 313M | Capitalization | 105M 14.54M 114M |
|---|---|---|---|---|---|
| Net income 2022 | 8M 1.11M 8.65M | Net income 2023 | -11M -1.52M -11.9M | EV / Sales 2022 | 0.62 x |
| Net Debt 2022 | 67.38M 9.31M 72.87M | Net Debt 2023 | 79.36M 10.96M 85.83M | EV / Sales 2023 | 0.64 x |
| P/E ratio 2022 |
20
x | P/E ratio 2023 |
-9.03
x | Employees | 537 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 18.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +34.29% | ||
| Current month | +44.62% | ||
| 1 month | +67.86% | ||
| 3 months | +9.30% | ||
| 6 months | +34.29% | ||
| Current year | +17.50% |
1 week
0.70
0.96
1 month
0.560.96
Current year
0.480.96
1 year
0.481.24
3 years
0.481.94
5 years
0.482.55
10 years
0.487.17
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Zhong Liu
DFI | Director of Finance/CFO | 59 | 93-12-31 |
Peng Chen
PSD | President | 50 | 21-12-06 |
Le Bin Wu
CHM | Chairman | 62 | 01-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guang Xia Gao
BRD | Director/Board Member | 59 | 06-12-31 |
Sheng Shen
BRD | Director/Board Member | 38 | 19-01-07 |
Qi Lu
BRD | Director/Board Member | 43 | 21-05-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.94 | 0.00% | 0 |
| 24-04-24 | 0.94 | +14.63% | 28,000 |
| 24-04-23 | 0.82 | 0.00% | 0 |
| 24-04-22 | 0.82 | +17.14% | 10,000 |
| 24-04-19 | 0.7 | 0.00% | 0 |
Delayed Quote Hong Kong S.E., April 25, 2024 at 04:09 am EDT
More quotes
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION is a China-based company principally engaged in the research and development, manufacture, sales and distribution of in-vitro diagnostics reagent products. The Companyâs products include mono diagnostic reagent products and double diagnostic reagent products. Its products categories include liver diseases category, kidney diseases category, lipid diseases category, cardiovascular diseases category, glycometabolism category, inorganic ion category, pancreas diseases category and specific protein category. Its products are sold to hospitals and medical institutions.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +17.50% | 17.37M | |
| -1.09% | 12.72B | |
| -12.53% | 7.5B | |
| +0.45% | 5.48B | |
| -1.37% | 4.61B | |
| +3.82% | 4.47B | |
| -52.66% | 3.28B | |
| +11.34% | 2.71B | |
| -19.05% | 2.02B | |
| -11.07% | 1.74B |
- Stock Market
- Equities
- 8247 Stock
